Efficacy and mechanisms of action of rmB7.2-Ig as an antitumor agent in combination with Adriamycin and Cytoxan chemotherapy
(c)2001 Elsevier Science.
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 101(2001), 3 vom: 07. Dez., Seite 303-14 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , , , , , , , |
| Format: | Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2001
|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.) |
| Schlagworte: | Journal Article Antigens, CD B7-2 Antigen CD86 protein, human Cd86 protein, mouse Immunoglobulin Heavy Chains Membrane Glycoproteins Recombinant Fusion Proteins Doxorubicin 80168379AG mehr... |
| Zusammenfassung: | (c)2001 Elsevier Science. The efficacy of chemotherapy for cancer is often limited by toxicity. Immune approaches to cancer immunotherapy, while promising for specificity and long-term protection, have not typically proven potent enough to generate significant therapeutic responses. We have shown therapeutic benefit using recombinant murine B7.2-Ig (rmB7.2-Ig) in murine tumor models. Efficacy was dependent on immune activity and was not associated with toxicity. Recently, the efficacy of rmB7.2-Ig was demonstrated in leukemia tumor models in combination with chemotherapeutic agents. To further explore the potential of this approach, we evaluated the efficacy in solid tumor models of rmB7.2-Ig given in combination with chemotherapeutics commonly used in clinical practice, testing the effects of dose and schedule. RmB7.2-Ig in combination with some chemotherapeutics enhances the activity and efficacy of reduced chemotherapeutic doses. However, the relative timing of chemotherapy and rmB7.2-Ig dosing can be important. Investigation of mechanisms of action based on histological studies suggests that inflammatory as well as T cell mechanisms comprise the response. Additional studies of mice deleted of B7.1, B7.2, and CTLA-4 suggest that the enhanced response induced by rmB7.2-Ig may not be mediated through CD28 ligation alone. The efficacy suggests potential for recombinant human B7.2-Ig as an adjuvant to chemotherapy in promoting immune-mediated mechanisms to augment the activity of chemotherapy |
|---|---|
| Beschreibung: | Date Completed 10.01.2002 Date Revised 16.11.2017 published: Print Citation Status MEDLINE |
| ISSN: | 1521-7035 |